Breaking News, Collaborations & Alliances

Harbour BioMed, Lannacheng Partner to Advance Next-Gen RDCs

Will integrate Harbour BioMed's expertise in antibody discovery with Lannacheng's strengths in radiopharmaceutical R&D and commercialization to accelerate the development of cancer therapies.

Author Image

By: Charlie Sternberg

Associate Editor

Harbour BioMed, a global biopharmaceutical company, has entered a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. to jointly advance the development of next-generation radionuclide drug conjugates (RDCs). Compared with conventional radiotherapy, RDCs utilize tumor antigen–specific ligands to deliver radionuclides directly to tumor lesions for targeted radiotherapy, thereby effectively reducing damage to surrounding healthy tissues. In contrast to antibody–drug...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters